Imagion Secures $3.75m for HER2+ Breast Cancer Trial
Key points
- Imagion Biosystems secures $3.75m in firm commitments
- Capital to fund Phase 1b/2 clinical trial
- FDA approval received for MagSense® imaging agent
Full summary
Imagion Biosystems Limited (ASX: IBX) has secured $3.75 million in firm commitments to fund the commencement of its Phase 1b/2 clinical trial for the MagSense® HER2 imaging agent. The capital raising, led by CPS Capital, follows FDA clearance of the Investigational New Drug (IND) application. The funds will support trial activation, drug manufacturing, IP development, and collaborations with MRI experts. The trial is expected to begin patient recruitment in Q3 2026.
Summary generated by a large language model. Please interpret with care.